Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397238 | 0.84 | TLR9 (0.38) | GRM5GPR119P2RX3ACHETLR9 | |
| SCHEMBL25169678 | 0.84 | PRMT5 (0.38) | GRM5GPR119ACHETLR9TLR7 | |
| SCHEMBL31129629 | 0.82 | GPR119 (0.43) | GPR119ACHETLR9TLR7CKS1B | |
| SCHEMBL25175382 | 0.82 | GRM5 (0.41) | GRM5GPR119ACHETLR9TLR7 | |
| SCHEMBL31129733 | 0.80 | GPR119 (0.47) | GPR119ACHETLR9TLR7 | |
| SCHEMBL27091565 | 0.80 | PRMT5 (0.44) | GPR119PRMT5 | |
| SCHEMBL26953611 | 0.79 | GRM5 (0.46) | GRM5GPR119ACHETLR9TLR7 | |
| SCHEMBL30659465 | 0.79 | GRM5 (0.46) | GRM5GPR119ACHETLR9TLR7 | |
| SCHEMBL30313313 | 0.78 | GRM5 (0.35) | GRM5GPR119P2RX3ACHETLR9 | |
| SCHEMBL3322484 | 0.78 | YAP1 (0.49) | GPR119PRMT5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | GRM5 3833/4885GPR119 1556/4885P2RX3 3255/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | GRM5 4299/4885GPR119 4038/4885P2RX3 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.